ImageSteamX

图像SteamX

• 批准号: 8052019
• 负责人: Timothy P. Bender
• 金额: $ 52万
• 依托单位: UNIVERSITY OF VIRGINIA
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-05-01 至 2012-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8052019
• 关键词: Address; Adopted; Apoptosis; Applications Grants; Automation; Biological Assay; Cell Cycle; Cell Cycle Proteins; Cells; Color; Communities; Core Facility; Fee-for-Service Plans; Flow Cytometry; Fluorescence Resonance Energy Transfer; Funding; Generations; Image; Immune; Individual; Journals; Laboratories; Lasers; Mitosis; National Center for Research Resources; Phagocytosis; Protein translocation; Proteins; Publications; Research; Research Personnel; Sampling; Secure; Services; Shapes; T-Lymphocyte; Technology; United States National Institutes of Health; Universities; Viral Load result; Virginia; Yeasts; base; cost effective; instrument; instrumentation; medical schools

DESCRIPTION (provided by applicant): The purpose of this NCRR Shared Instrument Grant application is to secure funding to purchase an ImageStreamX imaging flow cytometer for the Flow Cytometry Core Facility (FCCF) at the University of Virginia School of Medicine. The FCCF is a very heavily used core facility at the University of Virginia and provides flow cytometry related services on a fee for service basis to the University community in general and particularly to NIH funded investigators in the School of Medicine. The FCCF currently serves over 200 investigators from the laboratories of 95 PIs in 27 different departments. The FCCF purchased the first generation ImageStream100 in 2005 with funds from the School of Medicine and contributions from individual investigators, departments and centers within the SOM. This technology was quickly adopted by a number of investigators that led to several key publications early on. The University of Virginia has become well known as a leader in the use of this technology and has had 19 publications employing the technology, three of which have been featured on the cover of major Journals. The number of investigators utilizing this technology has continued to grow with currently 18 PIs using this technology in their research. Some of the common applications for which the instrument has been used have been studies of apoptosis, yeast cell cycle, protein translocation, protein colocalization, shape change assays, T cell-APC conjugate analysis, trogocytosis, phagocytosis, rare cell identification, viral load/replication, studies of cell cycle/mitosis, and morphological and phenotypical identification of functional immune cells. In many of these applications, studies have been compromised by the limitations of the current instrumentation, including the limited number of colors (markers) that can be simultaneously evaluated, slow acquisition rates, lack of sample automation, limited range of image magnification and the lack of appropriate laser excitation lines. In some cases, investigators have been unable to take advantage of this technology for certain applications such as FRET because the necessary laser excitation or channel separation is not available. With the introduction of the ImagestreamX, these limitations have been addressed and will allow our investigators to move projects forward more efficiently and in a cost effective manner. In addition, several investigators will be able to initiate studies that were not previously feasible with the Imagestream 100.

描述（由申请人提供）：本NCRR共享仪器资助申请的目的是确保为弗吉尼亚大学医学院流式细胞术核心设施（FCCF）购买ImageStreamX成像流式细胞仪的资金。FCCF是弗吉尼亚大学一个使用非常频繁的核心设施，并以服务费为基础向大学社区提供流式细胞术相关服务，特别是向NIH资助的医学院研究人员提供服务。目前，该基金为27个不同部门95个PI实验室的200多名调查人员提供服务。FCCF于2005年购买了第一代ImageStream 100，资金来自医学院，并由SOM内的个人研究者、部门和中心提供。这项技术很快就被许多研究人员采用，并在早期发表了几篇重要的论文。弗吉尼亚大学已经成为使用这项技术的领导者，并有19篇采用这项技术的论文，其中三篇登上了主要期刊的封面。使用这项技术的研究者数量持续增长，目前有18名PI在其研究中使用这项技术。该仪器已被用于的一些常见应用是细胞凋亡，酵母细胞周期，蛋白质易位，蛋白质共定位，形状变化测定，T细胞-APC缀合物分析，胞刺，吞噬作用，稀有细胞鉴定，病毒载量/复制，细胞周期/有丝分裂的研究，以及功能性免疫细胞的形态和表型鉴定。在许多这些应用中，研究受到当前仪器的限制，包括可同时评估的颜色（标记）数量有限、采集速率慢、缺乏样品自动化、图像放大范围有限以及缺乏适当的激光激发线。在某些情况下，研究人员无法利用这项技术的某些应用，如FRET，因为必要的激光激发或通道分离是不可用的。随着ImagestreamX的引入，这些限制已经得到解决，并将使我们的研究人员能够以更有效和更具成本效益的方式推进项目。此外，一些研究人员将能够启动以前无法使用Imagestomab 100进行的研究。